Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEGylated PYY3-36
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
PEGylated PYY3-36 (also known as RG7089) is a long-acting, polyethylene glycol (PEG)-conjugated peptide agonist of the neuropeptide Y receptor type 2 (NPY2R). Developed by Roche, it is a modified version of the endogenous gut hormone peptide YY (PYY3-36) designed to improve proteolytic stability and extend half-life. PEGylated PYY3-36 acts primarily on NPY2R to suppress appetite, reduce food intake, and improve glucose handling and insulin sensitivity. It was investigated for the treatment of obesity and type 2 diabetes (diabesity). However, development was discontinued due to target-related toxicity findings.
- Other names
- PEG-PYYPEG-PYY3-36PEG-PYY-3-36PEG-PYY 3-36PEGylated peptide YY (3-36)PEGylated peptide YY3-36
02
Targets
NPY1R (Neuropeptide Y receptor Y1)NPY4R (Neuropeptide Y receptor type 4)NPY5R (Neuropeptide Y receptor type 5)NPY2R (Neuropeptide Y receptor subtype 2)
Beyond the preview
Go deeper on PEGylated PYY3-36.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEGylated PYY3-36.